NorthWest Biotherapeutics Inc (NWBO)

[dennisdave]

One of the highlighted published concerns about this trial was the selection of patients, who, due to their favourable histology, resection %, genomic profile, age, tumour siting, performance status etc, had been selected over those with less promising prognosticators.
With those patients having an extended OS with or without the ‘vaccine’.
Moreover, Those with helpful MGMT status, showed a significant reduction in OS for having the vaccine. The latest European study showed that a very large % of this group had a life expectancy of 9.9 years.

If its published professor, then you will have no problem linking to the article where it has been found that this trial was the selection of patients, who, due to their favourable histology, resection %, genomic profile, age, tumour siting, performance status etc, had been selected over those with less promising prognosticators.

Tick tok tikc to Im waiting. Crickets